AllSci News
Enhertu expands to first-line breast cancer in U.S.
The US FDA approved a new indication for AstraZeneca/Daiichi Sankyo’s antibody drug conjugate (ADC) Enhertu (fam-trastuzumab deruxtecan-nxki; T-DxD), for use in combination…
Sanofi’s tolebrutinib falls short in Phase III for primary progressive MS
Sanofi disclosed topline results from the PERSEUS Phase III study evaluating tolebrutinib in primary progressive multiple sclerosis (PPMS), revealing that the investigational…
Sanofi confirms delay to tolebrutinib’s FDA review in nrSPMS
Sanofi announced that the US FDA review of its investigational Bruton’s tyrosine kinase (BTK) inhibitor tolebrutinib for non-relapsing secondary progressive multiple sclerosis…
AllSci Launches Hypothesis Publishing: A Seamless Way to Share, Connect, and Advance Scientific Ideas
North Bethesda, MD — December 15, 2025 — AllSci, the AI-powered research and discovery platform transforming how scientific knowledge is created and…
Pfizer’s Tukysa posts Phase 3 win as first-line maintenance in HER2+ breast cancer
Pfizer Inc. reported detailed results from the Phase 3 HER2CLIMB-05 trial showing that adding Tukysa (tucatinib) to first-line maintenance therapy significantly prolonged…
Lilly’s triple agonist retatrutide drives up to 28.7% weight loss and pain relief in Phase 3 TRIUMPH-4
Eli Lilly and Company’s investigational triple hormone receptor agonist retatrutide delivered substantial weight loss and meaningful relief from osteoarthritis pain in the…
Roche trumpets 30% cut to recurrence risk in ER+ breast cancer for SERD giredestrant
Roche announced that its experimental oral selective estrogen receptor degrader (SERD), giredestrant, significantly reduced the risk of invasive disease recurrence or death…
J&J’s Tecvayli combo delivers “remarkable” Phase 3 results in 2nd-line r/r MM
Johnson & Johnson (J&J)’s investigational combination of Tecvayli (teclistamab-cqyv) plus Darzalex Faspro (daratumumab + hyaluronidase) has shown remarkable efficacy in the Phase…
Hemab’s sutacimig set to be first prophylaxis for Glanzmann thrombasthenia
Denmark-based Hemab Therapeutics announced that its Phase 2 study for sutacimig in Glanzmann thrombasthenia (GT) delivered strong, “clinically meaningful” reductions in treated…
Pfizer boasts strong data for Hympavzi in inhibitor-positive hemophilia
Pfizer reported new Phase 3 data showing that Hympavzi (marstacimab) reduced treated annualized bleeding rate (ABR) by 93% compared with on-demand bypassing…
Praxis halts relutrigine trial early after efficacy signal in SCN2A/SCN8A epileptic encephalopathies
Praxis Precision Medicines said positive efficacy data have prompted the independent data monitoring committee to recommend an early stop to the registrational…
Capricor goes from HOPE-3 to promise after deramiocel’s Phase 3 success in Duchenne muscular dystrophy
Capricor Therapeutics trumpeted success in the pivotal Phase 3 HOPE-3 clinical trial for deramiocel as a treatment for boys and young men…
BMS’s CD19 CAR-T Breyanzi breaks ground with indication nod for MZL
Bristol Myers Squibb announced US FDA indication approval for Breyanzi (lisocabtagene maraleucel; liso-cel) as a treatment for adult patients with relapsed or…
BMS to continue Phase III ADEPT-2 for Cobenfy in Alzheimer’s-related psychosis after site irregularities
Bristol Myers Squibb will enrol additional patients into its Phase III ADEPT-2 trial of Cobenfy/KarXT (xanomeline/trospium) for psychosis associated with Alzheimer’s disease…
HopeMed takes fast-track status for first-in-class endometriosis antibody HMI-115
Shanghai, China-based biotech Hope Medicine Inc. (HopeMed) announced that the US FDA has granted Fast Track Designation (FTD) for HMI-115, the company’s…
The AllSci Brief
Free, systematic R&D and deal news. Daily.